- It is a type of cancer immunotherapy treatment that uses immune cells called T cells that are genetically altered in a lab to enable them in locating in destroying cancer cells more effectively.
Chimeric antigen receptor (CAR)-T cell therapy is a progressive new pillar in immune cell therapy for cancer. It has yielded remarkable clinical responses in patients with B-cell leukemia or lymphoma.
Diagrammatic representation of CAR-T cell Therapy
(1) T or NK cells are isolated from the patient’s or donor’s blood. (2) Subsequently, cells are genetically modified to express chimeric antigen receptors (CARs). (3) CAR-T or CAR-NK cells are expanded until sufficient cell numbers are attained and (4) (re-)injected into the patient’s body, where they can fight cancer cells. CAR constructs possess a targeting module that recognizes tumor antigens and either a single intracellular signaling domain (1. gen) or, one (2. gen), or two (3. gen) additional co-stimulatory domains. In most CAR constructs the targeting module consist of a single-chain variable fragment (scFv). Novel CAR constructs can also possess nanobodies, designed ankyrin repeat proteins (DARPins), ligands, or receptors instead of scFvs for target recognition. Adapter CARs consist of two components: a soluble antigen targeting module (TM) and a CAR which targets this TM. CAR chimeric antigen receptor, DARPins designed ankyrin repeat proteins, gen generation, scFv single-chain variable fragment, TM targeting module.
Capabilities
We are under process of development of Proof of concept for Cell and gene therapy. Our domain knowledge and expertise in research, process development and commercial scale give us an edge to tackle challenges associated with development of Biotech/biological product(s). We offer our expertise and support to biopharmaceutical and biotech companies for products, processes, and Quality management system (QMS).
